Endocrine Abstracts

Programmed cell death-1 (PD-1) receptor inhibitor is an immune check point blockade for anticancer treatment and is currently used for various malignancies such as melanoma, non-small cell lung cancer, and so on. However, an immune check point blockade is associated with a risk for immune related adverse events. Among these events, Type 1 diabetes is rare. We present a case of a 52-year-old man, with no previously diabetic history, who developed diabetic ketoacidosis (DKA) aft...